摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(ethoxymethylene)amino-3-allyl-2-thioxo-2,3-dihydro-1,3-thiazole-5-carbonitrile | 1225513-84-7

中文名称
——
中文别名
——
英文名称
4-(ethoxymethylene)amino-3-allyl-2-thioxo-2,3-dihydro-1,3-thiazole-5-carbonitrile
英文别名
4-(ethoxymethylene)-amino-3-(allyl)-2-thioxo-1,3-thiazole-5-carbonitrile;ethyl N-(5-cyano-3-prop-2-enyl-2-sulfanylidene-1,3-thiazol-4-yl)methanimidate
4-(ethoxymethylene)amino-3-allyl-2-thioxo-2,3-dihydro-1,3-thiazole-5-carbonitrile化学式
CAS
1225513-84-7
化学式
C10H11N3OS2
mdl
——
分子量
253.349
InChiKey
DTTYNJLPEJVCKJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    16
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    106
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(ethoxymethylene)amino-3-allyl-2-thioxo-2,3-dihydro-1,3-thiazole-5-carbonitrile盐酸氨基脲三乙胺 作用下, 以 乙醇 为溶剂, 反应 13.0h, 以90%的产率得到(7-imino-3-allyl-2-thioxo-3,7-dihydro-2H-thiazolo[4,5-d]pyrimidin-6-yl)urea
    参考文献:
    名称:
    [EN] A NOVEL 3-SUBSTITUTED 7-IMINO-2-THIOXO-3, 7-DIHYDRO-2H-THIAZOLO [4,5-DI PYRIMIDIN-6-YL - AND PROCESS FOR PREPARATION THEREOF
    [FR] (7-IMINO-2-THIOXO-3,7-DIHYDRO-2H-THIAZOLO[4,5-D]PYRIMIDIN-6-YLE SUBSTITUÉ EN POSITION 3 INÉDIT ET SON PROCÉDÉ DE PRÉPARATION
    摘要:
    公开号:
    WO2011061754A9
  • 作为产物:
    描述:
    4-氨基-3-烯丙基-2-硫代-2,3-二氢-1,3-噻唑-5-甲腈原甲酸三乙酯对甲苯磺酸 作用下, 以 甲苯 为溶剂, 反应 6.0h, 以65%的产率得到4-(ethoxymethylene)amino-3-allyl-2-thioxo-2,3-dihydro-1,3-thiazole-5-carbonitrile
    参考文献:
    名称:
    Novel 8-(furan-2-yl)-3-substituted thiazolo [5,4-e][1,2,4] triazolo[1,5-c] pyrimidine-2(3H)-thione derivatives as potential adenosine A2A receptor antagonists
    摘要:
    Novel thiazolotriazolopyrimidine derivatives (23-33) designed as potential adenosine A(2A) receptor (A(2A)R) antagonists were synthesized. Molecular docking studies revealed that all compounds (23-33) exhibited strong interaction with A(2A)R. The strong interaction of the compounds (23-33) with A(2A)R in silico was confirmed by their high binding affinity with human A(2A)R stably expressed in HEK293 cells using radioligand-binding assay. The compounds 24-26 demonstrated substantial binding affinity and selectivity for A(2A)R as compared to SCH58261, a standard A(2A)R antagonist. Decrease in A(2A)R-coupled release of endogenous cAMP in treated HEK293 cells demonstrated in vitro A(2A)R antagonist potential of the compounds 24-26. Attenuation in haloperidol-induced motor impairments (catalepsy and akinesia) in Swiss albino male mice pre-treated with compounds 24-26 further supports their role in the alleviation of PD symptoms. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2010.02.048
点击查看最新优质反应信息

文献信息

  • Synthesis of novel 7-imino-2-thioxo-3,7-dihydro-2H-thiazolo [4,5-d] pyrimidine derivatives as adenosine A2A receptor antagonists
    作者:Pratibha Mehta Luthra、Chandra Bhushan Mishra、Pawan Kumar Jha、Sandeep Kumar Barodia
    DOI:10.1016/j.bmcl.2009.11.133
    日期:2010.2
    Novel bicyclic thiazolopyrimidine compounds (15-26) were synthesized to develop adenosine A(2A) receptor (A(2A)R) antagonist for the treatment of Parkinson's disease (PD). The binding affinity of the compounds (15-26) with A(2A)R was evaluated using radioligand binding assay on isolated membranes from stably transfected HEK293 cells. Selectivity of the compounds towards A(2A)R was assessed by comparing their binding affinities with A(1) receptors (A(1)R). cAMP concentrations were measured from HEK293 cells treated with compounds (15-26) as compared to NECA (A(2A)R agonist). The compound (16) possessed strongest A(2A)R binding affinity (K-i value = 0.0038 nM) and selectivity (737-fold) versus A(1)R. Decrease in A(2A)R-coupled release of endogenous cAMP from HEK293 cells treated with compounds (15-26) is evocative of their potential as A(2A)R antagonist. (C) 2009 Elsevier Ltd. All rights reserved.
查看更多